Vulvovaginal candidosis

Lancet. 2007 Jun 9;369(9577):1961-71. doi: 10.1016/S0140-6736(07)60917-9.


Despite therapeutic advances, vulvovaginal candidosis remains a common problem worldwide, affecting all strata of society. Understanding of anti-candida host defence mechanisms in the vagina has developed slowly and, despite a growing list of recognised risk factors, a fundamental grasp of pathogenic mechanisms continues to elude us. The absence of rapid, simple, and inexpensive diagnostic tests continues to result in both overdiagnosis and underdiagnosis of vulvovaginal candidosis. I review the epidemiology and pathogenesis of this infection, and also discuss management strategies.

Publication types

  • Review

MeSH terms

  • Antifungal Agents / therapeutic use*
  • Candidiasis, Vulvovaginal* / diagnosis
  • Candidiasis, Vulvovaginal* / drug therapy
  • Candidiasis, Vulvovaginal* / etiology
  • Female
  • Humans
  • Severity of Illness Index


  • Antifungal Agents